NCT03449641

Brief Summary

The role of different levels of compliance and long-term effects of positive airway pressure (PAP) therapy on gas exchange, sleepiness, quality of life, depression and death rate in patients with obesity hypoventilation syndrome (OHS).

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
252

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jun 2009

Typical duration for not_applicable

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2009

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2012

Completed
5.7 years until next milestone

First Submitted

Initial submission to the registry

February 22, 2018

Completed
6 days until next milestone

First Posted

Study publicly available on registry

February 28, 2018

Completed
Last Updated

March 1, 2018

Status Verified

February 1, 2018

Enrollment Period

3 years

First QC Date

February 22, 2018

Last Update Submit

February 28, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • Effects of positive airway pressure (PAP) therapy on gas exchange

    Effects of positive airway pressure (PAP) therapy on arterial blood gases measurements

    2 years

Secondary Outcomes (4)

  • Effects of positive airway pressure (PAP) therapy on sleepiness

    2 years

  • Effects of positive airway pressure (PAP) therapy on quality of life

    2 years

  • Effects of positive airway pressure (PAP) therapy on depression

    2 years

  • Effects of positive airway pressure (PAP) therapy on death rate

    2 years

Study Arms (1)

Positive airway pressure (PAP) treatment

OTHER

Positive airway pressure (PAP),which reverses upper airway obstruction, is effective in the majority of patients with stable obesity hypoventilation syndrome (OHS).

Device: Positive airway pressure (PAP)

Interventions

Positive airway pressure (PAP) is a mode of respiratory ventilation used in the treatment of sleep apnea.

Positive airway pressure (PAP) treatment

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • aged between 18 and 80 years
  • Obesity hypoventilation syndrome diagnosis (OHS)
  • clinically stable for at least 4 weeks prior to the enrolmenT
  • above-elementary school education.

You may not qualify if:

  • refusal to participate
  • refusal of PAP therapy
  • central sleep apnea syndromes
  • restrictive ventilation syndromes
  • severe congestive heart failure
  • a history of life-threatening arrhythmias
  • severe cardiomyopathy
  • significant chronic kidney disease
  • untreated hypothyroidism
  • family or personal history of mental illness
  • drug or alcohol abuse
  • sedative use
  • severe cognitive impairment
  • concurrent oncological diseases
  • history of narcolepsy or restless legs syndrome.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Bouloukaki I, Mermigkis C, Michelakis S, Moniaki V, Mauroudi E, Tzanakis N, Schiza SE. The Association Between Adherence to Positive Airway Pressure Therapy and Long-Term Outcomes in Patients With Obesity Hypoventilation Syndrome: A Prospective Observational Study. J Clin Sleep Med. 2018 Sep 15;14(9):1539-1550. doi: 10.5664/jcsm.7332.

MeSH Terms

Conditions

Obesity Hypoventilation Syndrome

Condition Hierarchy (Ancestors)

Sleep Apnea, ObstructiveSleep Apnea SyndromesApneaRespiration DisordersRespiratory Tract DiseasesHypoventilationRespiratory InsufficiencySleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System DiseasesObesityOverweightOvernutritionNutrition DisordersNutritional and Metabolic Diseases

Study Officials

  • Sophia Schiza, MD, PhD

    University of Crete

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

February 22, 2018

First Posted

February 28, 2018

Study Start

June 1, 2009

Primary Completion

June 1, 2012

Study Completion

June 1, 2012

Last Updated

March 1, 2018

Record last verified: 2018-02